NYXH Key Statistics, Chart & Performance
The current stock price of NYXH is 4.8 USD. In the past month the price decreased by -4.57%. In the past year, price decreased by -41.85%.
NYXH Latest News, Press Relases and Analysis
NYXH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.83 | 224.14B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.61 | 203.30B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.43 | 150.59B | ||
| SYK | STRYKER CORP | 28.18 | 141.95B | ||
| IDXX | IDEXX LABORATORIES INC | 59.7 | 60.12B | ||
| BDX | BECTON DICKINSON AND CO | 13.45 | 55.61B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.72 | 50.29B | ||
| RMD | RESMED INC | 25.84 | 37.34B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.43 | 36.44B | ||
| DXCM | DEXCOM INC | 34.12 | 24.75B | ||
| PODD | INSULET CORP | 71.6 | 23.02B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 12.05 | 19.33B |
Related stock screener links
About NYXH
Company Profile
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
Company Info
NYXOAH SA
Rue Edouard Belin 12
Mont-Saint-Guibert BRABANT-WALLON BE
CEO: Olivier Taelman
Employees: 184
Phone: 3226121755
NYXOAH SA / NYXH FAQ
What does NYXH do?
Nyxoah SA is a medical technology company, which engages in the development and commercialization of solutions to treat Obstructive Sleep Apnea (OSA). The company is headquartered in Mont-Saint-Guibert, Brabant-Wallon and currently employs 184 full-time employees. The company went IPO on 2020-09-18. The firm focuses on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The system consists of a neurostimulator, which is implanted close to the nerve of the tongue, as well as an activation chip, which is connected to a disposable patch and is positioned every night by the patient under the chin.
What is the current price of NYXH stock?
The current stock price of NYXH is 4.8 USD. The price increased by 2.78% in the last trading session.
What is the dividend status of NYXOAH SA?
NYXH does not pay a dividend.
What is the ChartMill rating of NYXOAH SA stock?
NYXH has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How many employees does NYXOAH SA have?
NYXOAH SA (NYXH) currently has 184 employees.
Can you provide the market cap for NYXOAH SA?
NYXOAH SA (NYXH) has a market capitalization of 206.54M USD. This makes NYXH a Micro Cap stock.
What is the next earnings date for NYXH stock?
NYXOAH SA (NYXH) will report earnings on 2026-03-11, after the market close.
NYXH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to NYXH. When comparing the yearly performance of all stocks, NYXH is a bad performer in the overall market: 90.44% of all stocks are doing better.
NYXH Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NYXH. NYXH has a bad profitability rating. Also its financial health evaluation is rather negative.
NYXH Financial Highlights
Over the last trailing twelve months NYXH reported a non-GAAP Earnings per Share(EPS) of -2.59. The EPS decreased by -30.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -66.28% | ||
| ROE | -105.18% | ||
| Debt/Equity | 0.29 |
NYXH Forecast & Estimates
14 analysts have analysed NYXH and the average price target is 14.63 USD. This implies a price increase of 204.85% is expected in the next year compared to the current price of 4.8.
For the next year, analysts expect an EPS growth of -24.84% and a revenue growth 57.01% for NYXH